KalVista Pharmaceuticals received FDA approval for its oral drug Ekterly (sebetralstat), targeting acute swelling attacks in hereditary angioedema (HAE) patients aged 12 and older. This marks the first oral, on-demand treatment option competing against injectable therapies like Takeda’s Firazyr and Pharming's Ruconest. The approval followed a delay due to FDA resource constraints but was backed by Phase III data demonstrating rapid symptom relief and tolerability. KalVista’s stock surged following the announcement, reflecting optimism about the drug’s market potential, which could peak at $600 million annually in the US. The drug’s dosing flexibility and competitive pricing aim to expand on-demand HAE treatment options.